搜尋結果

共 2024 個結果
頁數:1...22 23 24 25 26 27 28 29 30 ...102

The dilemma Hong Kong confronts

... y and all COVID-19 cases – through targeted treatments, of course. Let us now consider the second option – that is, reopening Hong Kong to the world at large. The benefits are apparent. We’re a financ ...More

EJ Insight2022-02-07

高盛:藥明發盈喜 連升3日重上80元 留意貼價購18980、高槓桿購19984,貼牛50177

... 進執行現存及新引進的COVID-19項目,料截至去年十二月底止年度利潤及歸屬於公司權益股東的利潤,按年分別增長 ...全文

港股360輪證攻略2022年02月07日

【異動股】藥明生物升3% 料全年純利增近倍

... 進執行現存及新引進的COVID-19項目,以及集團新的非新冠綜合項目收益和市場份額顯著增加等。 其他主要的生物 ...全文

即時新聞港股直擊2022年02月07日

Submerged by COVID

... impact of COVID-19 on human capital formation. Though negative everywhere, the effects are likely to be especially severe in emerging markets. Few emerging markets possess the high-speed broadband nee ...More

EJ Insight2022-02-04

Fed under pressure to tighten rates more rapidly

... sitive to COVID-19 has picked up rapidly over the past six months. Other measures of underlying inflation, such as the trimmed mean or sticky CPI, paint a similar picture. And the broad-based increase ...More

EJ Insight2022-01-31

How much has the pandemic cost?

As the COVID-19 pandemic entered its third year, the United States was enjoying a protracted stock-market boom, and China’s global trade surplus had reached record highs. There is reason to believe th ...More

EJ Insight2022-01-28

Minimize the impact of ransomware attack

Dealing with a ransomware attack during the COVID-19 pandemic could be a nightmare scenario. According to a ransomware report, the average ransomware payment in the first half of 2021 Q1 was US$ 0.57 ...More

EJ Insight2022-01-28

COVID-19 mess: We need an exit strategy

... nt of the COVID-19 virus. Whether it be the mega-cluste ...全文

今日信報時事評論EJ InsightBrian Wong2022年01月28日

The necessary rise of Africa's health tech

... sponse to COVID-19 has spurred innovation – and investment – in the sector. Health tech in Africa attracted more funding in 2020 than ever before. African health-tech start-ups can grow quickly becaus ...More

EJ Insight2022-01-27

The nightmare of being the close contact person

Something is worse than Omicron. It is bad to be infected with Covid-19, but even worse if you are deemed as the close contact person. Hong Kong people are bracing for a not very Happy New Year next w ...More

EJ Insight2022-01-26

能否預測Omicron影響何時結束

兩年多來,2019年冠狀病毒疾病(COVID-19)大流行一直影響着我們的社交、財務和其他日常活動。截至今年1 ...全文

今日信報時事評論蘇家培 朱文英 羅鳳儀2022年01月26日

COVID-19 mess: We need an exit strategy

... nt of the COVID-19 virus. Whether it be the mega-cluster in Kwai Chung, the allegedly-hamster-induced outbreak in Causeway Bay, or, indeed, the Kwun Tong cluster – one fact is clear, Omicron is here, ...More

EJ Insight2022-01-25

Employment prospects in 2030

... d how the COVID-19 epidemic has affected the company’s digital transformation strategy released by the consulting firm McKinsey in the middle of the year. The survey, conducted early this year, interv ...More

EJ Insight2022-01-24

Domino's調度得宜 疫境中化危為機

... 在這幾年(新冠肺炎叫COVID-19,今年已是2022年!)「被迫」養成的習慣亦難以逆轉。Domino's在這 ...全文

今日信報理財投資上善若水姚穎謙2022年01月22日

從攀緣看Omicron

... ron的變異,要先從COVID-19的病毒說起,它的最大特徵是表面像皇冠的棘蛋白,這是和人體細胞結合的「鑰匙」 ...全文

今日信報副刊文化拾趣人生岑逸飛2022年01月22日

How Facebook became the opium of the masses

... imes more COVID-19 vaccine disinformation than the average American. The situation is so dire, and government action so inept, that Czechs rely on civil society – including volunteers known as the Cze ...More

EJ Insight2022-01-21

三葉草生物-B(02197) 其他-業務發展最新情況

... 實其預防所有嚴重程度COVID-19的保護效力(155KB, pdf) ...全文

即時新聞港交所通告2022年01月21日

撥開陰霾見青天

... 或綜合後遺症症狀的「COVID-19後遺症」。這是由一系列不同的疾病組成,其中有急性的、慢性的或兩者兼有,並且 ...全文

今日信報副刊文化天祐醫言黃天祐醫生2022年01月20日

聯泰控股(00311) 盈利警告 / 內幕消息

聯泰控股(00311) 盈利預告及有關COVID-19疫苗接種率的最新情況(329KB, pdf) ...全文

即時新聞港交所通告2022年01月19日

【輪證贏家】恒指彈高 「人道」對Put

... 就咁樣因為幾隻驗到有COVID-19嘅病毒而成批「人道」不得停,仲要講明喺上年12月22日買咗倉鼠嘅,麻煩主人 ...全文

即時新聞即巿股評2022年01月19日

頁數:1...22 23 24 25 26 27 28 29 30 ...102

信報簡介 | 服務條款 | 私隱條款 | 免責聲明 | 廣告查詢 | 加入信報 | 聯絡信報

股票及指數資料由財經智珠網有限公司提供。期貨指數資料由天滙財經有限公司提供。外滙及黃金報價由路透社提供。

本網站的內容概不構成任何投資意見,本網站內容亦並非就任何個別投資者的特定投資目標、財務狀況及個別需要而編製。投資者不應只按本網站內容進行投資。在作出任何投資決定前,投資者應考慮產品的特點、其本身的投資目標、可承受的風險程度及其他因素,並適當地尋求獨立的財務及專業意見。本網站及其資訊供應商竭力提供準確而可靠的資料,但並不保證資料絕對無誤,資料如有錯漏而令閣下蒙受損失,本公司概不負責。